Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$12.72 - $34.47
Next Earnings Date
Jun 04 2025 (Estimate)
Next Earnings Date
Jun 04 2025 (Est.)
Latest price
Market Cap | $2.45B |
EV | $2.08B |
Shares Outstanding | 172.13M |
Beta | 0.81 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $45.15 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | -15.50% |
Operating Cash Flow | -37.00% |
Free Cash Flow | -37.00% |
Revenue | - |
EPS | -18.40% |
Operating Cash Flow | -35.30% |
Free Cash Flow | -30.90% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | -89.97% |
ROCE 2024 | -52.91% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Immunovant, Inc.
IMVT
Sector
Healthcare
Industry
Biotechnology
CEO
Salzmann, Peter
Employees
207
Website
immunovant.comIPO Date
2019-06-21
Headquarters
320 West 37th Street, 6th Floor, New York, New York, 10018, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved